These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38835116)

  • 1. Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.
    Lee YK; Heo HH; Kim N; Park UH; Youn H; Moon EY; Kim EJ; Um SJ
    BMB Rep; 2024 Jun; 57(6):299-304. PubMed ID: 38835116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
    Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells.
    Sakurai E; Maesawa C; Shibazaki M; Yasuhira S; Oikawa H; Sato M; Tsunoda K; Ishikawa Y; Watanabe A; Takahashi K; Akasaka T; Masuda T
    Int J Oncol; 2011 Sep; 39(3):665-72. PubMed ID: 21687938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
    De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
    Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress.
    Bansal N; Kadamb R; Mittal S; Vig L; Sharma R; Dwarakanath BS; Saluja D
    PLoS One; 2011; 6(10):e26156. PubMed ID: 22028823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a.
    Yang TY; Teng CJ; Lin TC; Chen KC; Hsu SL; Wu CC
    Int J Cancer; 2018 Jan; 142(1):92-108. PubMed ID: 28884479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.
    Schenk T; Stengel S; Goellner S; Steinbach D; Saluz HP
    Genes Chromosomes Cancer; 2007 Sep; 46(9):796-804. PubMed ID: 17534929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function.
    Pascucci FA; Ladelfa MF; Toledo MF; Escalada M; Suberbordes M; Monte M
    Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118918. PubMed ID: 33279609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling.
    Xu Y; Rong LJ; Meng SL; Hou FL; Zhang JH; Pan G
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1057-63. PubMed ID: 27049257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.
    Tajeddine N; Gala JL; Louis M; Van Schoor M; Tombal B; Gailly P
    Cancer Res; 2005 Aug; 65(16):7348-55. PubMed ID: 16103086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.
    Epping MT; Wang L; Edel MJ; Carlée L; Hernandez M; Bernards R
    Cell; 2005 Sep; 122(6):835-47. PubMed ID: 16179254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway.
    Bandyopadhyay D; Mishra A; Medrano EE
    Cancer Res; 2004 Nov; 64(21):7706-10. PubMed ID: 15520174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
    Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
    J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
    Schefler AC; Koca E; Bernicker EH; Correa ZM
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.
    Kewitz S; Staege MS
    PLoS One; 2013; 8(2):e55897. PubMed ID: 23409080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPRR2A enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity.
    Mizuguchi Y; Specht S; Lunz JG; Isse K; Corbitt N; Takizawa T; Demetris AJ
    BMC Mol Biol; 2012 Jun; 13():20. PubMed ID: 22731250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
    Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
    Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
    Monte M; Simonatto M; Peche LY; Bublik DR; Gobessi S; Pierotti MA; Rodolfo M; Schneider C
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11160-5. PubMed ID: 16847267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.